Global Cord Blood (NYSE:CO) Earns Strong-Buy Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Global Cord Blood (NYSE:CO) in a research report released on Monday morning. The firm issued a strong-buy rating on the medical research company’s stock.

Global Cord Blood Stock Performance

Shares of CO opened at $1.25 on Monday. The stock has a market cap of $151.94 million, a PE ratio of 1.95 and a beta of 0.16. Global Cord Blood has a fifty-two week low of $2.03 and a fifty-two week high of $5.50. The firm’s 50-day simple moving average is $1.37 and its two-hundred day simple moving average is $1.36.

About Global Cord Blood

Global Cord Blood operates as a holding company, which engages in the provision of cord blood banking services. It provides cord blood processing and storage service. The company also offers cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services. The firm preserves cord blood units donated by the public and provides matching services on such donated units and deliver matching units to patients in need of transplants.